Compare APC & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APC | CGEM |
|---|---|---|
| Founded | 2025 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 920.0M | 904.7M |
| IPO Year | N/A | 2020 |
| Metric | APC | CGEM |
|---|---|---|
| Price | $20.68 | $13.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $21.75 | ★ $30.13 |
| AVG Volume (30 Days) | 141.5K | ★ 900.4K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | ★ 10.99% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.47 | N/A |
| Revenue Next Year | $4.20 | $5.20 |
| P/E Ratio | $25.80 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.08 | $5.68 |
| 52 Week High | $21.72 | $16.74 |
| Indicator | APC | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 61.44 | 42.75 |
| Support Level | $17.43 | $12.41 |
| Resistance Level | $21.72 | $16.21 |
| Average True Range (ATR) | 0.71 | 0.94 |
| MACD | 0.07 | -0.16 |
| Stochastic Oscillator | 64.98 | 11.57 |
Arko Petroleum Corp is a fuel distribution company. It operates through three reportable segments: i) Wholesale: Distributes fuel to gas stations, sub-wholesalers, and bulk purchasers, typically under long-term contracts on a cost-plus or consignment basis. ii) Fleet Fueling: Operates proprietary and third-party cardlock locations serving commercial and municipal fleets, and earns commissions from proprietary fuel card sales. iii) GPMP: Supplies fuel to ARKO Retail Sites at cost plus a fixed margin, charges fixed fees to certain sites. The company generates the majority of revenue from the Wholesale segment.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.